SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-21-000008
Filing Date
2021-03-31
Accepted
2021-03-31 16:15:03
Documents
16
Period of Report
2021-03-31
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K tars-20210331.htm   iXBRL 8-K 35851
2 EX-99.1 exhibit991tarsus3312021pre.htm EX-99.1 69780
8 picture11.jpg GRAPHIC 5866
  Complete submission text file 0001819790-21-000008.txt   271543

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20210331.xsd EX-101.SCH 2411
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tars-20210331_cal.xml EX-101.CAL 702
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tars-20210331_def.xml EX-101.DEF 1635
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20210331_lab.xml EX-101.LAB 24975
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20210331_pre.xml EX-101.PRE 13179
9 EXTRACTED XBRL INSTANCE DOCUMENT tars-20210331_htm.xml XML 11788
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 21793466
SIC: 2836 Biological Products, (No Diagnostic Substances)